- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06784960
Kommunikationsstrategier for at øge hensigten med HPV-vaccination
En klynge randomiseret kontrolleret forsøg, der tester kommunikationsstrategier for at øge HPV-vaccinationsintentionen: et undersøgelseseksperiment
This research aims to identify communication strategies to improve the uptake of vaccines using an experimental design, focusing on the Human Papillomavirus (HPV) vaccine, which is highly effective in preventing HPV-related cancers. However, low HPV vaccination rates among adults remain a significant public health challenge. Although randomized controlled trials (RCTs) have demonstrated that interventions can increase vaccine uptake in children, few RCTs have been conducted among adults.
To address this gap, a multidisciplinary investigative team with expertise in communication, medicine, nursing, and behavior-change intervention research will conduct a survey experiment and a cluster randomized controlled trial. First, a national sample of adults ages 18 to 45 who have not received the HPV vaccine or are unsure of their vaccination status will participate in a survey experiment to identify the most promising theory-based messages to strengthen HPV vaccine intentions. The two messages associated with the largest increases in vaccination intentions will then be selected for further testing.
Next, 16 Penn Medicine primary care clinics will participate in a factorial cluster randomized controlled trial to test patient-level and clinic-level interventions designed to increase HPV vaccine uptake. Patient-level interventions will include theory-based text messages and a reminder-only message condition. The clinic-level intervention will provide healthcare providers with feedback on missed opportunities for HPV vaccination and a toolkit to support strong HPV vaccine recommendations.
The study will evaluate whether these interventions increase receipt of the first HPV vaccine among eligible adult patients and whether combining patient-directed messages with the clinic-level intervention further increases HPV vaccination. HPV vaccination will be assessed using Penn Medicine electronic health records and, when needed, patient self-report.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- University of Pennsylvania
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18-45 years old
Exclusion Criteria:
- Under 18 and over 45 years old
- Received HPV vaccine or unsure about receipt
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: HPV Message 1 + Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. |
|
Eksperimentel: HPV Message 1 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Eksperimentel: HPV Message 2 + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Eksperimentel: HPV Message 2 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Eksperimentel: HPV Message 3 + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Eksperimentel: HPV Message 3 + No Clinic Intervention
|
A patient-directed text-message intervention promoting HPV vaccination, selected from the Aim 1 survey experiment based on its effect on HPV vaccination intentions. |
|
Aktiv komparator: Control Message + Clinic Intervention
|
A clinic-level intervention providing primary care providers with a toolkit supporting strong HPV vaccine recommendations. An attention-matched control text-message condition that does not contain the theory-based HPV vaccination messages being evaluated. |
|
Aktiv komparator: Control Message + No Clinic Intervention
|
An attention-matched control text-message condition that does not contain the theory-based HPV vaccination messages being evaluated. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Aim 1 - Intention to Vaccinate
Tidsramme: Immediately after exposure to the assigned message
|
Assessed using a three-item validated HPV Vaccination Intention Scale. The three items evaluate the participant's intent, plan, and likelihood to receive the HPV vaccine within the next 6 months. Responses for each item were recorded on a 5-point Likert scale. A composite intention score was calculated as the mean of the three items, with total scores ranging from 1 to 5. Higher scores indicate a better outcome (a greater intention to receive the HPV vaccine). |
Immediately after exposure to the assigned message
|
|
Aim 2 - Receipt of HPV Vaccine
Tidsramme: From intervention initiation through 9 months of follow-up
|
Receipt of HPV vaccine during the follow-up period, determined from HPV vaccination documentation in the electronic health record or patient self-report. |
From intervention initiation through 9 months of follow-up
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Patologiske processer
- Sygdomsegenskaber
- Infektioner
- Virussygdomme
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- DNA-virusinfektioner
- Tumorvirusinfektioner
- Patologiske tilstande, tegn og symptomer
- Opførsel
- Behandlingsoverholdelse og compliance
- Sundhedsadfærd
- Afslag på behandling
- Vaccinationsafslag
- Papillomavirus infektioner
- Meddelelse
- Vaccinationstøven
Andre undersøgelses-id-numre
- UPCC 02026
- 856892 (Anden identifikator: University of Pennsylvania IRB)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .